Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2024-02-11
Target enrollment:
Participant gender:
Summary
This is a Phase III trial to study the effectiveness of nimotuzumab versus cisplatin combined
with intensity-modulated radiation therapy (IMRT) in treating patients with stage II-III
nasopharyngeal carcinoma.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University First Affiliated Hospital, Sun Yat-Sen University Guangdong General Hospital Guangdong Provincial People's Hospital